Literature DB >> 31641553

Stereotactic body radiotherapy for an isolated splenic metastasis from ovarian carcinoma.

Ryan T Hughes1, Michael H Soike1, Surendra Prajapati1, Andrew Q Lin2, James D Ververs1, Adrianna H Masters1, Corbin A Helis1, A William Blackstock1, Michael K Farris1.   

Abstract

Splenic metastases from oligometastatic ovarian carcinoma are a rare occurrence. Usual treatment for splenic metastases includes splenectomy, but some patients are either unable or unwilling to undergo surgery. Stereotactic body radiotherapy (SBRT) is an effective ablative modality for treating metastatic disease. SBRT to abdominopelvic tumors has been shown to be safe and effective for properly-selected patients and is particularly attractive in the oligometastatic setting as an alternative to radical resection. In this case study, we report a patient with an isolated splenic metastasis from ovarian carcinoma treated with 50 Gy in 10 fractions.
© 2019 Old City Publishing, Inc.

Entities:  

Keywords:  isolated splenic metastasis; ovarian carcinoma; spleen metastasis; stereotactic body radiotherapy

Year:  2019        PMID： 31641553      PMCID： PMC6774492     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  9 in total

1.  Metastatic tumors to the spleen: a 25-year clinicopathologic study.

Authors:  K Y Lam; V Tang
Journal:  Arch Pathol Lab Med       Date:  2000-04       Impact factor: 5.534

2.  Splenomegaly and solitary spleen metastasis in solid tumors.

Authors:  B Klein; M Stein; A Kuten; M Steiner; D Barshalom; E Robinson; D Gal
Journal:  Cancer       Date:  1987-07-01       Impact factor: 6.860

3.  Splenic metastases--not a frequent problem, but an underestimate location of metastases: epidemiology and course.

Authors:  Jörg Sauer; Karin Sobolewski; Klaus Dommisch
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-21       Impact factor: 4.553

4.  Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Authors:  W Jeffrey Petty; James J Urbanic; Tamjeed Ahmed; Ryan Hughes; Beverly Levine; Kyle Rusthoven; Michael Papagikos; Jimmy R Ruiz; Brian E Lally; Michael Chan; Hollins Clark; Ralph B D'Agostino; A William Blackstock
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-07-10       Impact factor: 7.038

5.  Distant metastases in ovarian carcinoma.

Authors:  G Cormio; C Rossi; A Cazzolla; L Resta; G Loverro; P Greco; L Selvaggi
Journal:  Int J Gynecol Cancer       Date:  2003 Mar-Apr       Impact factor: 3.437

6.  UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy.

Authors:  G G Hanna; L Murray; R Patel; S Jain; K L Aitken; K N Franks; N van As; A Tree; P Hatfield; S Harrow; F McDonald; M Ahmed; F H Saran; G J Webster; V Khoo; D Landau; D J Eaton; M A Hawkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-10-13       Impact factor: 4.126

7.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

8.  Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Authors:  Puneeth Iyengar; Zabi Wardak; David E Gerber; Vasu Tumati; Chul Ahn; Randall S Hughes; Jonathan E Dowell; Naga Cheedella; Lucien Nedzi; Kenneth D Westover; Suprabha Pulipparacharuvil; Hak Choy; Robert D Timmerman
Journal:  JAMA Oncol       Date:  2018-01-11       Impact factor: 31.777

9.  Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature.

Authors:  Meiling Lv; Yuyao Li; Changqin Luo; Peijun Liu; Jin Yang
Journal:  Exp Ther Med       Date:  2014-01-24       Impact factor: 2.447
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.